Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Pazopanib (Votrient®) is recommended as an option for use within NHS Wales for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy. This recommendation applies only in circumstances where the approved Patient Access Scheme is utilised |
|||
|
|||
Medicine details |
|||
| Medicine name | pazopanib (Votrient®) | ||
| Formulation | 200 mg film-coated tablet and 400 mg film-coated tablet | ||
| Reference number | 549 | ||
| Indication | Treatment of adult patients with selective subtypes of advanced soft tissue sarcoma who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy |
||
| Company | Novartis Pharmaceuticals UK Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Submission type | Full | ||
| Status | Recommended | ||
| Advice number | 2513 | ||
| NMG meeting date | 20/02/2013 | ||
| AWMSG meeting date | 16/10/2013 | ||
| Ratification by Welsh Government | 02/12/2013 | ||
| Date of issue | 03/12/2013 | ||
| Date of last review | 01/12/2016 | ||
| Commercial arrangement | PAS | ||